| HOME >> MEDICINE >> TECHNOLOGY |
3.1.4 Forecasts
3.1.4.1 Sales Value
3.1.4.2 Annual Cost of Therapy
3.1.4.3 Patient Volume
3.1.4.4 Treatment Usage Patterns
3.1.4.5 Future Impact
3.1.5 Drug Sales
3.1.5.1 Overview
3.1.6 Pricing & Reimbursements
3.1.6.1 Pricing of Drugs in France
3.1.6.2 Reimbursement Policy in France
3.2 Key Takeaway
4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.2.1 Clinical Endpoints Benchmarking
4.1.2.2 Safety Profile
4.1.2.3 Annual Cost of Therapy
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.2.1 Market Share Analysis of Drugs
4.3 Product Profiles
4.3.1 Avastin (bevacizumab)
4.3.1.1 Overview
4.3.1.2 Efficacy
4.3.1.3 Safety
4.3.1.4 Clinical Study Details
4.3.1.5 Annual Cost of Therapy
4.3.1.6 Regulatory Approvals
4.3.1.7 Life Cycle Management Activities
4.3.1.8 Product Positioning
4.3.1.9 Sales Forecast
4.3.2 Erbitux (cetuximab)
4.3.2.1 Overview
4.3.2.2 Efficacy
4.3.2.3 Safety
4.3.2.4 Clinical Study Details
4.3.2.5 Annual Cost of Therapy
4.3.2.6 Regulatory Approvals
4.3.2.7 Life Cycle Management Activities
4.3.2.8 Product Positioning
4.3.2.9 Sales Forecast
4.3.3 Xeloda (capecitabine)
4.3.3.1 Overview
4.3.3.2 Efficacy
4.3.3.3 Safety
4.3.3.4 Clinical Study Details
4.3.3.5 Regulatory Approvals
4.3.3.6 Life Cycle Management Activities
4.3.3.7 Annual Cost of Therapy
4.3.3.8 Product Positioning
4.3.3.9 Sales Forecast
4.3.4 Vectibix (panitumumab)
4.3.4.1 Overview
4.3.4.2 Efficacy
4.3.4.3 Safety
4.3.4.4 Clinical Study Details
4.3.4.5 Regulatory Approvals
4.3.4.6 Lif
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |